Esophageal Cancer Market Growth Trajectory Through 2024-2033

The Esophageal Cancer Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Esophageal Cancer Market:
https://www.thebusinessresearchcompany.com/report/esophageal-cancer-global-market-report

According to The Business Research Company’s Esophageal Cancer Global Market Report 2024, The esophageal cancer market size has grown rapidly in recent years. It will grow from $1.25 billion in 2023 to $1.38 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to increased number of cancer, improvement in healthcare infrastructure, rise in alcohol consumption, growth in demand for preventive healthcare solutions, increase in prevalence of esophageal adenocarcinoma.

The esophageal cancer market size is expected to see strong growth in the next few years. It will grow to $1.94 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to rising prevalence of esophageal cancer, increasing public understanding of healthcare, improvements in healthcare infrastructure, chronic consumption of smoking and alcohol, increasing prevalence of esophageal adenocarcinoma. Major trends in the forecast period include technological advancements in treatment options, increased investment in research and development, increasing utilization of precision medicine, development of targeted therapies, increased participation in clinical trials and collaborations between academia, pharmaceutical companies, and healthcare institutions.

An increase in esophageal cancer is expected to propel the esophageal cancer market growth. Esophageal cancer is a malignancy that affects the esophagus, the tube-like structure connecting the throat to the stomach. As the incidence of esophageal cancer increases, there will be a higher demand for diagnostic procedures, such as endoscopy, imaging tests, and biopsies, to detect and confirm the presence of the disease. For instance, in February 2023, according to the National Library of Medicine, a US-based medical library operated by the American government, the incidence rate of esophageal adenocarcinoma among individuals aged 40–65 is projected to rise from 2.12 per 100,000 persons in 2021 to 3.86 per 100,000 persons in 2040. This represents an 82% increase over 19 years, equivalent to a yearly growth rate of 3.2%. Therefore, the increase in esophageal cancer is expected to drive the growth of the esophageal cancer market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12637&type=smp

The esophageal cancer market covered in this report is segmented –

1) By Type: Esophageal Squamous-Cell Carcinoma, Esophageal Adenocarcinoma, Other Types
2) By Treatment Type: Chemotherapy, Targeted Therapy, Other Treatment Types
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End Users: Hospitals, Homecare, Specialty Centers, Other End Users

New drug approval is a key trend gaining popularity in the esophageal cancer market. Major companies operating in the esophageal cancer market are focused on obtaining new drug approvals to strengthen their position and gain a competitive advantage. For instance, in May 2022, Bristol Myers Squibb, a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for its two products, including Opdivo (nivolumab) (injection for intravenous use) and Opdivo plus Yervoy (ipilimumab). Its primary therapeutic approaches are for individuals diagnosed with advanced or metastatic esophageal squamous cell carcinoma (ESCC). The authorization was granted following the Phase 3 clinical trial evaluation, which demonstrated enhanced overall survival rates among patients who received these medications.

The esophageal cancer market report table of contents includes:

1. Executive Summary
2.Esophageal Cancer Market Characteristics
3.Esophageal Cancer Market Trends And Strategies
4.Esophageal Cancer market analysis
5. Esophageal Cancer Market Size And Growth
6. Esophageal Cancer Segmentation
7.Esophageal Cancer Regional And Country Analysis
.
.
.
27.Esophageal Cancer Competitive Landscape And Company Profiles
28.Esophageal Cancer Key Mergers And Acquisitions
29.Esophageal Cancer Future Outlook and Potential Analysis

TOP MAJOR PLAYERS:

• Pfizer Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model